• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Otolaryngology Ear, Nose & Throat

Lyra Therapeutics appoints new chief medical officer

July 5, 2022 By Sean Whooley

Lyra Therapeutics chief medical officer Richard Neiman

Lyra Therapeutics (Nasdaq:LYRA) announced today that it appointed Dr. Richard Nieman as its new chief medical officer (CMO). Nieman’s appointment as CMO of Lyra, which develops the XTreo — a platform for enabling precise, sustained and local delivery of medications to the ear, nose and throat (ENT) passages and other diseased tissues — will be […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Implants, Otolaryngology Ear, Nose & Throat, Personnel, Pharmaceuticals, Respiratory Tagged With: Lyra Therapeutics, Personnel, Personnel Moves

Medtronic completes Intersect ENT acquisition

May 13, 2022 By Sean Whooley

Medtronic Intersect ENT

Medtronic (NYSE:MDT) announced that it completed its previously announced $1.1 billion acquisition of Intersect ENT (Nasdaq:XENT). Fridley, Minnesota-based Medtronic announced in August 2021 that it would acquire all outstanding shares of the Menlo Park, Calif.-based sinus implant maker for $28.25 per share in an all-cash transaction. As a result of the transaction, Medtronic acquires Intersect ENT’s Propel and Sinuva drug-eluting […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Implants, Mergers & Acquisitions, Otolaryngology Ear, Nose & Throat Tagged With: Intersect ENT Inc., Medtronic

Impel NeuroPharma rebrands to Impel Pharmaceuticals as part of corporate transformation

April 25, 2022 By Sean Whooley

Impel Neuropharma logo updated

Impel NeuroPharma (Nasdaq:IMPL) announced today that it changed its name to Impel Pharmaceuticals as part of a corporate rebrand. Seattle-based Impel develops proprietary Precision Olfactory Delivery (POD) technology to treat patients suffering from diseases across a range of areas in addition to the central nervous system. The company’s Trudhesa nasal spray for treating migraine in […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Neurological, Otolaryngology Ear, Nose & Throat, Pharmaceuticals Tagged With: Impel NeuroPharma Inc., Impel Pharmaceuticals

Lyra Therapeutics closes $100.5M private placement

April 13, 2022 By Sean Whooley

Lyra Therapeutics LYR-210

Lyra Therapeutics (Nasdaq:LYRA) announced today that it closed its previously announced private placement worth $100.5 million. The company announced last week that, in the private placement, investors had the option in the private placement to purchase either shares of Lyra’s common stock at $4.22 per share or, in lieu thereof, pre-funded warrants to purchase shares […]

Filed Under: Auto-injectors, Business/Financial News, Drug-Device Combinations, Featured, Funding Roundup, Otolaryngology Ear, Nose & Throat, Pharmaceuticals, Respiratory Tagged With: Lyra Therapeutics

Lyra Therapeutics announces $100.5M private placement

April 8, 2022 By Sean Whooley

Lyra Therapeutics LYR-210

Lyra Therapeutics (Nasdaq:LYRA) announced today that it agreed to sell securities in a private placement worth more than $100 million. The company — which develops the XTreo platform designed to enable precise, sustained, and local delivery of medications to the ear, nose and throat (ENT) passages and other diseased tissues — did not list an […]

Filed Under: Auto-injectors, Business/Financial News, Drug-Device Combinations, Featured, Funding Roundup, Otolaryngology Ear, Nose & Throat, Respiratory Tagged With: Lyra Therapeutics

Lyra Therapuetics initiates Phase 3 trial for chronic rhinosinusitis treatment

January 24, 2022 By Sean Whooley

Lyra Therapeutics LYR-210

Lyra Therapeutics (NSDQ:LYRA) announced today that it initiated the Phase 3 Enlighten I trial for its LYR-210 treatment. Watertown, Massachusetts-based Lyra’s Phase 3 Enlighten I clinical trial will evaluate LYR-210, delivered through Lyra’s proprietary XTreo drug-eluting implant, in adult, surgically naïve chronic rhinosinusitis (CRS) patients. The company designed LYR-210 for delivery in a brief, non-invasive, […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Implants, Otolaryngology Ear, Nose & Throat, Pharmaceuticals Tagged With: Lyra Therapeutics

Lyra Therapeutics appoints new CFO

September 13, 2021 By Sean Whooley

Lyra Therapeutics LYR-210

Lyra Therapeutics (NSDQ:LYRA) announced today that it appointed Jason Cavalier as its new chief financial officer, effective today. Cavalier succeeds the company’s current CFO, Don Elsey, who is retiring while he remains expected to serve in an advisory role to assist with the transition. Watertown, Massachusetts-based Lyra — which develops the XTreo platform designed to […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Implants, Otolaryngology Ear, Nose & Throat Tagged With: Lyra Therapeutics, Personnel, Personnel Moves

Lyra touts non-human trial of XTreo drug-eluting implant

September 10, 2021 By Sean Whooley

Lyra Therapeutics LYR-210

Lyra Therapeutics (NSDQ:LYRA) is touting preclinical data for its XTreo drug-eluting implant for dosing in local sinus tissues. Watertown, Massachusetts-based Lyra’s preclinical results were published — “Drug Release and Pharmacokinetic Evaluation of Novel Implantable Mometasone Furoate Matrices in Rabbit Maxillary Sinuses” — were published online in the peer-review journal, American Journal of Rhinology & Allergy. The […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Implants, Otolaryngology Ear, Nose & Throat Tagged With: Lyra Therapeutics

Impel NeuroPharma prices $45M offering following FDA approval for migraine treatment

September 10, 2021 By Sean Whooley

Impel Neuropharma logo updated

Impel NeuroPharma (NSDQ:IMPL) announced that it priced an underwritten public offering of common stock worth $45 million. The offering includes 3 million shares of common stock priced to the public at $15 per share, with gross proceeds set to total $45 million before deducting underwriting discounts and commissions and other offering expenses payable by Impel […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Funding Roundup, Neurological, Otolaryngology Ear, Nose & Throat, Pharmaceuticals Tagged With: Impel NeuroPharma Inc.

AFYX touts trial of biodegradable drug delivery patch

September 7, 2021 By Sean Whooley

AFYX Therapeutics

AFYX Therapeutics today touted results from a study exploring the delivery of antibody fragments using the company’s Rivelin technology. The preclinical study, conducted in collaboration with the University of Sheffield in the United Kingdom, evaluated Rivelin for delivering the antibody fragments directly to inflamed tissue in mucosal diseases. According to a news release, results demonstrated […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Otolaryngology Ear, Nose & Throat Tagged With: AFYX Therapeutics

  • Go to page 1
  • Go to page 2
  • Go to page 3
  • Interim pages omitted …
  • Go to page 8
  • Go to Next Page »

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech 100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Souring
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS